TC
LCTX icon

TFS Capital’s Lineage Cell Therapeutics LCTX Stock Holding History

TFS Capital’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-208,472
Closed -$575K – 198
2017
Q2 		$575K Buy
+208,472
New +$582K 0.23% 151
2015
Q4 		– Sell
-42,290
Closed -$102K – 825
2015
Q3 		$102K Sell
42,290
-298,972
-88% -$774K 0.01% 803
2015
Q2 		$1M Buy
341,262
+320,719
+1,561% +$1.24M 0.1% 341
2015
Q1 		$82K Buy
+20,543
New +$71.1K 0.01% 899

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

TFS Capital's LCTX Position: Q3 2017 in Review

TFS Capital sold out of Lineage Cell Therapeutics (LCTX) in Q3 2017, closing a stake of 208,472 shares — an estimated $575K sold.

TFS Capital first reported a position in LCTX in Q1 2015 and held it in 4 quarters. The position peaked at $1M in Q2 2015. 102 funds tracked by Wall St. Rank hold LCTX as of Q3 2017.

  • TFS Capital reported no remaining Lineage Cell Therapeutics position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 208,472 Lineage Cell Therapeutics shares in Q3 2017, an estimated $575K.
  • TFS Capital first reported a position in Lineage Cell Therapeutics in Q1 2015 and held it in 4 quarters.
  • TFS Capital's Lineage Cell Therapeutics position peaked at $1M in Q2 2015.
  • 102 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.